

Charity registration number 1163211

Company registration number CE004367 (England and Wales)

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

**PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
LEGAL AND ADMINISTRATIVE INFORMATION**

Trustees	G Boyle J M M Domingos P Perez Librero C P Likar A Moretti T Shaish A S Butler B J Magennis K Wouters	(Appointed 27 June 2023) (Appointed 27 June 2023) (Appointed 27 June 2023)
Key Personnel	Rusell Patten Dominic Graham Lisa Wong	Director General Operations Director Finance Manager
Charity number	1163211	
Company number	CE004367	
Registered office	Lynwood House Crofton Road Orpington Kent BR6 8QE	
Independent examiner	Louise Hallsworth, FCA Baxter & Co Chartered Certified Accountants Lynwood House, Crofton Road Orpington Kent BR6 8QE	

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) CONTENTS

	Page
Trustees' report	1 - 7
Independent examiner's report	8
Statement of financial activities	9
Balance sheet	10
Notes to the financial statements	11 - 19

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) FOR THE YEAR ENDED 31 DECEMBER 2023

The trustees present their annual report and financial statements for the year ended 31 December 2023.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charity's constitution, the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019).

Objectives and activities

The trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the charity should undertake.

Research: a new workstream

Research Steering Group

To make sure the new Parkinson's Europe [research strategy](#) truly reflects the voice of the Parkinson's community, we created a Research Steering Group (RSG) in Q3 2022. The group represents our key stakeholders (people affected by Parkinson's, healthcare professionals, Parkinson's Europe Member Organisations and the treatment industry), and will focus and deliver on our research offer.

Research Strategy

The RSG's initial work was to guide the creation of the Parkinson's Europe Research Strategy, based on insights gathered from our Member Organisations and treatment industry partners about their patient involvement and engagement activities in the research space. The RSG then helped with the development and translation of the Research Strategy Executive Summary into nine languages.

The Research Strategy was then launched in Q2 2023 with a [new webpage](#) and a social media campaign, which achieved 11,500 impressions and 600 engagements.

Our Research Strategy will ensure all stakeholders have a clear understanding of Parkinson's Europe's aims and ambitions in the research space – and will be the foundation to deliver on our [Strategic Goal 4](#).

For more information about our activities on research, please contact amelia@parkinsonseurope.org.

Parkinson's Europe Engagement Network

Parkinson's Europe recognised the need to reach more people across Europe in a strategic and constructive way, to share calls to action that would help us achieve our current and future strategic activities and support the many significant advancements for the Parkinson's community that are continually taking place in different areas (such as research, advocacy and knowledge sharing).

Having secured funding from CRO company IQVIA in 2023, we developed the technical infrastructure to make the Parkinson's Europe Engagement Network ([PEN](#)) possible. The PEN is an online network designed to connect people affected by Parkinson's with opportunities they can actively take part in that will impact their future. People who sign up to the PEN will benefit by having opportunities they are interested in sent directly to them via email, according to their own interests and preferences.

In the development phase, we involved our stakeholders when discussing how the PEN would function; we then connected with all our volunteers and friends (a mix of organisations and individuals) to support the alpha and beta phases of testing of the network.

The PEN was launched in December 2023, and we have been actively promoting engagement since then. Opportunities shared with the PEN members in the initial weeks had a very high rate of interest and participation – supporting the delivery of our [Strategic Goals 3 and 4](#).

For more information about the PEN, please contact amelia@parkinsonseurope.org.

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Our advocacy activities at the European level

Campaign advocating for a ban of glyphosate

In 2023, the licence for the use of glyphosate – a herbicide associated with a perceived higher risk of developing Parkinson's – ended in the European Union (EU). A renewal process was started by a list of companies and led by the European Commission. To combat this plan, Parkinson's Europe started an advocacy campaign calling for the glyphosate licence *not* to be renewed for another 10 years. Instead, we asked that the licence be extended for only one year, to allow time to carry out further independent scientific research on glyphosate's safety.

Our [campaign](#) started in November 2023, involving a number of our Member Organisations and other Parkinson's organisations, as well as other pan-European organisations (including PAN Europe and EFNA) and important KOLs from the medical and scientific world. Our stakeholders joined a Parkinson's Europe-led pan-European campaign, and were provided information and lobbying materials that we developed such as information sheets, letter templates, social media content and press releases.

We also reached out to our online community via social media, news articles, press releases and social media infographics translated into six languages. The online campaign achieved:

- 31,000 impressions
- 1,800 engagements
- 175 new followers
- 1,100 visits to the Parkinson's Europe campaign webpage.

Although glyphosate was re-approved for 10 years in late November 2023 by the European Commission, we will continue our efforts to lobby against glyphosate and seek to involve more and a broader range of stakeholders. This campaign work supports our [Strategic Goals](#) 2 and 3.

Parkinson's Advocacy Group Forum

The treatment industry is a key stakeholder in the Parkinson's community, and we therefore acknowledge the need to involve industry representatives in our political advocacy work.

In October 2023, we launched the Parkinson's Advocacy Group (PAG) Forum, which brings together representatives of our Member Organisations as well as of our industry partners with the purpose of exploring political advocacy issues on which we could work together to find synergies and achieve win-win results for all parties.

The PAG Forum will be meeting regularly every three months. These meetings deliver great value both to Parkinson's Europe, our members and our industry partners, in support of our [Strategic Goal](#) 3.

For more information about our political advocacy activities, please contact russell@parkinsonseurope.org, fiona@parkinsonseurope.org or adrien@parkinsonseurope.org.

Our global reach, engagement and collaboration

World Parkinson's Day 2023

World Parkinson's Day (WPD) is one of Parkinson's Europe's key focuses, and for 2023 our key campaign objectives were:

1. To support members and the wider Parkinson's community to raise awareness of Parkinson's via their own campaigns and activities
2. To showcase and promote campaigns across the globe on our online map and social media campaign
3. To gain support for World Parkinson's Day to be officially recognised and observed as a global health day.

With our 2023 campaign, we aimed to primarily reach and engage with local, national, regional and international Parkinson's organisations, as well as with global health organisations (such as the World Health Organisation, WHO). In addition, we also targeted individuals affected by Parkinson's, influencers, the academic world and the industry.

We consistently involved and supported our Member Organisations throughout the planning and development of the campaign by:

- producing a [campaign toolkit](#)
- organising a communications workshop
- adding our Members' events to our online WPD map.

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

On an individual level, anyone from the Parkinson's community was able to join our call to raise the profile and increase the recognition of WPD across the world.

We produced a wide array of campaign communication materials (meeting updates, e-shots, social media posts, website updates, [articles](#)) to make sure all our partners and Members were aware of our plans and how to get involved. Our Members and all organisations involved benefited by having a platform to amplify their campaigns, which helped increase awareness of Parkinson's in general – consistently with our [Strategic Goals](#) 2 and 3.

The figures below show the wide reach and engagement of our campaign:

- 90 events recorded from 40 countries
- 1,000+ supported us to make WPD an official world health day
- [What does Parkinson's mean to me?](#) was the most viewed video ever for Parkinson's Europe
- 3,800 engagements on social media
- 355,000 impressions (1,430% increase compared with 2022)
- 350 new followers
- 5,000 visitors to the Parkinson's Europe website
- 34,000 video views
- 340% increase in engagements.

World Parkinson Congress 2023

The World Parkinson Congress (WPC) is the only international Parkinson's congress. The 2023 edition was held in Barcelona, Spain, and it saw a very high participation from the European Parkinson's community – it was therefore a key event for Parkinson's Europe to attend and be actively engaged with.

Parkinson's Europe's key goals from participating in the WPC were:

1. Networking, engagement and increasing brand awareness
4. Scientific, research and working group input
5. Fundraising and engagement with the treatment industry
6. To develop an advocacy plan to shape political thinking and engagement.

We supported our Member Organisations to attend the WPC, providing a €1,000 grant to seven organisations.

Members of the Parkinson's Europe Team, including our Director General, were consistently involved in the WPC Leadership Forum and supporting Working Groups in the years leading up to the WPC, which meant that our organisation helped shape the Congress agenda and priority focus.

By attending the WPC, we achieved a significant level of engagement and interaction with all Parkinson's community stakeholders – which will help us deliver all our four [Strategic Goals](#):

- +350 followers, 169,000 impressions and 7,000 engagements to our social media campaign
- Dozens of individuals completed the 'Connect with us' forms at the Parkinson's Europe booth
- Engagement with 30 new Parkinson's organisations
- 15 meetings with treatment industry companies (pharmaceutical and technology)
- 150+ people attended our social networking event
- 4 poster presentations
- 1 prestigious Robin A Elliott Award for Outstanding Community Service awarded to Parkinson's Europe co-founder Lizzie Graham.

For more information about our global stakeholder engagement activities, please contact fiona@parkinsonseurope.org.

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Online communication: delivering information and boosting Parkinson's awareness

Our new website

The Parkinson's Europe website had not had a major upgrade or restructure in several years, and we discovered it was no longer serving our audience in the best way – making it harder for users to find what they need, and affecting our SEO and traffic potential as a result.

As our website serves the whole Parkinson's community and is a key part of our organisation's brand and offering, we needed to develop a new platform to better meet the needs of our audience, increase our traffic, and help us communicate our core goals and campaigns in a more effective, up-to-date and impactful way.

The new website redevelopment kicked off in the summer of 2023, involving a web design agency, and launched in March 2024. Several of our industry partners sponsored this work and to whom we are most grateful.

Throughout the process, we carried out user surveys with people from the Parkinson's community and key stakeholders to understand what they would like from the new website.

Our website is crucial to our 4 [Strategic Goals](#), and the new website's core features have been designed to support and enhance all of them. The new platform will be easier to navigate, and will include new functionalities such as:

- An exclusive area for our Member Organisations to share resources and information
- An interactive map to help users find relevant events, initiatives, research and information in their country
- Integrating our online magazine Parkinson's Life into the new website.

Growing our social media presence

While enjoying a strong presence across all our core social media channels ([Twitter/X](#), [Facebook](#), [LinkedIn](#) and [Instagram](#)) for years, we wanted to accelerate our growth, engagement and overall impact on social media in 2023 to help us achieve all four [Strategic Goals](#) more widely, and deliver a positive impact by amplifying the voices and messages of people with Parkinson's, our Member Organisations and our industry partners.

Activity took off in early 2023 and is currently ongoing. It has so far seen the active participation of:

- people with Parkinson's, who helped us create several meaningful videos to help our key campaigns for the year
- our Member Organisations, who were involved in social media workshops and in our different awareness campaigns
- our industry partners, as we ran several successful partner campaigns on social media.

All these stakeholders received significant exposure and engagement thanks to Parkinson's Europe sharing their content to a growing and increasingly engaged audience.

Throughout 2023, our social media presence has grown significantly:

- our social media audience grew by 20% to 26,000 followers
- our post engagement grew by 167% to an average of 120 engagements per post (across our four main channels) compared with 2022
- our post impressions grew by 9% in 2023 despite spending significantly less on paid advertisements and posting less frequently than 2022 (according to our new 'quality over quantity' approach)
- for the first time, we consistently got more than 100 likes per post on Instagram, and also got our first two posts with more than 200 likes.

This growth has helped us boost our influence, as we were able to share and interact with key figures in 2023 such as the WHO (on World Parkinson's Day), Paul McCartney (during the WPC), and Jeremy Paxman. It also helped boost our brand visibility by developing a consistent visual brand identity on social media.

For more information about our communication work, please contact laura@parkinsonseurope.org.

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Collaboration with the treatment industry

Parkinson's Europe has a 30-year history of positive and fruitful collaboration with the treatment industry – a key stakeholder in the Parkinson's community and a key player in the development of new treatments – and hopefully a cure – for Parkinson's.

We often engage in important mutually beneficial partnership projects with our industry partners that aim to benefit the wider European Parkinson's community. Below are two examples of successful projects we developed or concluded in 2023.

Parkinson's Europe would like to sincerely thank our treatment industry partners for providing funding and support to our activities in 2023. For more information about our funding partners, please visit [here](#). **For more information about the projects below and our collaboration with the industry, please contact francesco@parkinsonseurope.org.**

Multi-company working group on device-assisted therapies

Device-assisted therapies (DATs) have proven effective in improving the quality of life of people with Parkinson's. Yet, testimonies and evidence increasingly tell us that not all people who may be suitable for these treatments receive them – which results in sub-optimal treatment and reduced quality of life for people with Parkinson's, their families and caregivers.

Understanding this challenge, Parkinson's Europe invited representatives of companies developing infusion pumps for levodopa, infusion pumps for apomorphine and deep brain stimulation devices to join a working group to a) explore common challenges and b) identify possible joint actions to improve people with Parkinson's engagement with – and access to – DATs.

The working group firstly identified, mapped and prioritised specific challenges and pinch points in the pathway from the development of a DAT product to its distribution – pointing out common challenges along the way and identifying those that are considered as a priority and which fall within the work remit of Parkinson's Europe. The group subsequently agreed to develop a knowledge-sharing resource aimed at people with Parkinson's and their families to increase their awareness of DATs and empower them to discuss these therapy options with healthcare professionals. This work will continue in 2024.

This project is successfully bringing together different stakeholders to collaborate and share knowledge and good practices from their existing work areas (consistent with our [Strategic Goal 2](#)). It also aims to develop information resources aimed at people with Parkinson's and their families (consistent with our [Strategic Goal 1](#)).

Survey on awareness of advanced Parkinson's and treatment options

Evidence and testimonies show that a significant number of people with Parkinson's may be at the advanced Parkinson's stage but are not gaining access to, or information about, appropriate available treatment options. Topics such as symptom progression and decline in the effectiveness of oral medication are not always discussed with healthcare professionals – potentially resulting in sub-optimal treatments and reduced quality of life.

In 2021, Parkinson's Europe (in collaboration with industry partner Britannia Pharmaceuticals) launched an online [multi-language survey](#) focused on advanced Parkinson's and awareness about treatment options.

The results showed, among other things, that people with Parkinson's experience variations in effects of oral medications, but lack expert advice. The full results were published in three scientific posters (presented at three international scientific congresses, in 2022 and 2023). In June 2023, a [report](#) aimed at the Parkinson's community was published and disseminated widely, helping to increase the knowledge and awareness (both among people with Parkinson's and healthcare professionals, consistent with our [Strategic Goals 1 and 3](#)) about advanced Parkinson's diagnosis, management and treatment options.

Although this project is now concluded, the results of this survey are being used to inform further work carried out around the topic of advanced Parkinson's and non-oral therapies.

In 2023, Parkinson's Europe secured 20 funding partners. We would like to sincerely thank each and every one of them for providing funding and support to our activities in 2023. For more information about all of Parkinson's Europe's [partners](#), please visit our [partners](#) web page."

**PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023**

Financial review

During the year under review there was a decrease of £53,031 (2022: decrease of £245,750) on unrestricted funds and restricted funds introduced of £44,942.

At the time of approving the financial statements, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements. The Association's reserve policy is to hold reserves only to cover a period of 3 to 6 months administration costs. No additional reserves are intended to be held.

It is the policy of the charity that unrestricted funds which have not been designated for a specific use should be maintained at a level equivalent to between three and six month's expenditure. The trustees consider that reserves at this level will ensure that, in the event of a significant drop in funding, they will be able to continue the charity's current activities while consideration is given to ways in which additional funds may be raised. This level of reserves has been maintained throughout the year.

Structure, governance and management

The charity was established by a charitable trust deed on 25th April 1998 in Belgium and registered as a Charitable Incorporated Organisation in the UK on 19th August 2015.

The trustees have had regard to the Charity Commission's guidance on public benefit.

The trustees, who are also the directors for the purpose of company law, and who served during the year and up to the date of signature of the financial statements were:


G Boyle	
V Clark	(Resigned 27 June 2023)
J M M Domingos	
L Graham	(Resigned 27 June 2023)
D J Lavender MBE	(Resigned 27 June 2023)
P Perez Librero	
C P Likar	
A Moretti	
T Shaish	
A S Butler	(Appointed 27 June 2023)
B J Magennis	(Appointed 27 June 2023)
K Wouters	(Appointed 27 June 2023)

The following individuals were observer trustees during the period:

A Butler (Resigned June 2023)
B Magennis (Resigned June 2023)
B Morandi (Resigned June 2023)
K Wouters (Resigned June 2023)

**PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023**

The trustees' report was approved by the Board of Trustees.



J M M Domingos

Trustee

Date: Wednesday 26 June 2024

**PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
INDEPENDENT EXAMINER'S REPORT
TO THE TRUSTEES OF PARKINSON'S EUROPE**

I report to the trustees on my examination of the financial statements of Parkinson's Europe (the charity) for the year ended 31 December 2023.

Responsibilities and basis of report

As the trustees of the charity (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 (the 2006 Act).

Having satisfied myself that the financial statements of the charity are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the charity's financial statements carried out under section 145 of the Charities Act 2011 (the 2011 Act). In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.


Independent examiner's statement

Since the charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of FCA, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the charity as required by section 386 of the 2006 Act; or
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
- 4 the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.



Louise Hallsworth, FCA

Baxter & Co
Chartered Certified Accountants
Lynwood House, Crofton Road
Orpington
Kent
BR6 8QE

Dated: 26 June 2024....

**PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
STATEMENT OF FINANCIAL ACTIVITIES
INCLUDING INCOME AND EXPENDITURE ACCOUNT**

FOR THE YEAR ENDED 31 DECEMBER 2023

	Notes	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £	Unrestricted funds 2022 £
Income from:					
Donations and legacies	3	24,134	-	24,134	22,472
Charitable activities	4	455,211	98,241	553,452	301,867
Investments	5	478	-	478	25
Total income		479,823	98,241	578,064	324,364
Charitable activities	6	517,385	53,299	570,684	575,003
Net income/(expenditure)		(37,562)	44,942	7,380	(250,639)
Other recognised gains and losses:					
Other gains/(losses)	12	(15,469)	-	(15,469)	4,889
Net movement in funds		(53,031)	44,942	(8,089)	(245,750)
Reconciliation of funds:					
Fund balances at 1 January 2023		101,494	-	101,494	347,244
Fund balances at 31 December 2023		48,463	44,942	93,405	101,494

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

**PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
BALANCE SHEET**

AS AT 31 DECEMBER 2023

	Notes	2023 £	£	2022 £	£
Current assets					
Debtors	13	56,726		60,431	
Cash at bank and in hand		221,438		237,147	
		<u>278,164</u>		<u>297,578</u>	
Creditors: amounts falling due within one year	14	184,759		196,084	
Net current assets			<u>93,405</u>		<u>101,494</u>
The funds of the charity					
Restricted income funds	16		44,942		-
Unrestricted funds			48,463		101,494
			<u>93,405</u>		<u>101,494</u>

The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 December 2023.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the trustees on Wednesday 26 June 2024

Josefa Maria Mate Domingos

J M M Domingos

Trustee

Company registration number CE004367 (England and Wales)

**PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023**

1 Accounting policies

Charity information

Parkinson Europe (formerly European Parkinson's Disease Association) is a Charitable Incorporated Organisation registered in the UK on 19 August 2015.

1.1 Accounting convention

The financial statements have been prepared in accordance with the charity's Charity's trust deed, the Companies Act 2006, FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019). The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities not to prepare a Statement of Cash Flows.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors or grantors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

**PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023**

1 Accounting policies (Continued)

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use.

Irrecoverable VAT is charged against the expenditure heading for which it was incurred.

1.6 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities (if any). During the current and prior year there is no overdraft facility has been used on Parkinson's Europe's bank accounts.

1.7 Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

**PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023**

1 Accounting policies (Continued)

1.8 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.9 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.10 Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3 Income from donations and legacies

	Unrestricted funds 2023 £	Unrestricted funds 2022 £
Donations and gifts	3,718	3,581
Membership fees	20,416	18,891
	<u>24,134</u>	<u>22,472</u>

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

4 Income from charitable activities

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £
Core income	298,307	98,241	396,548	246,968	-	246,968
Project income	154,146	-	154,146	134,173	-	134,173
Other income	2,758	-	2,758	(79,274)	-	(79,274)
	<u>455,211</u>	<u>98,241</u>	<u>553,452</u>	<u>301,867</u>	<u>-</u>	<u>301,867</u>

5 Income from investments

	Unrestricted funds 2023 £	Unrestricted funds 2022 £
Interest receivable	478	25
	<u>478</u>	<u>25</u>

6 Expenditure on charitable activities

	Charitable activities 2023 £	Charitable activities 2022 £
Direct costs		
Member organisation and board meetings	9,181	15,636
Advocacy communication and project development	118,943	89,700
Funded projects	43,313	59,445
Other direct costs	7,140	407
Freelancer costs	111,258	180,742
	<u>289,835</u>	<u>345,930</u>
Share of support and governance costs (see note 7)		
Support	274,625	226,503
Governance	6,224	2,570
	<u>570,684</u>	<u>575,003</u>
Analysis by fund		
Unrestricted funds	517,385	575,003
Restricted funds	53,299	-
	<u>570,684</u>	<u>575,003</u>

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

6 Expenditure on charitable activities

(Continued)

Included within share of supports costs are wages and salary costs amounting to £10,536 (2022: £13,654) directly attributable to member organisation, board meetings and advocacy in addition to the £17,582 (2022: £15,636) shown above, therefore the total spend for member organisation and board meetings in 2023 amounts to £28,118 (2022: £29,260).

7 Support costs allocated to activities

	2023	2022
	£	£
Staff costs	262,481	210,412
Technology costs	3,319	2,944
Bad debts	192	241
Bank charges	314	256
Bookkeeping costs	3,960	3,886
Other support costs	2,685	3,831
Travel costs	560	3,857
Insurance	1,114	1,076
Governance costs	6,224	2,570
	<u>280,849</u>	<u>229,073</u>
Analysed between:		
Charitable activities	<u>280,849</u>	<u>229,073</u>

8 Trustees

During the year, payments totalling £8,239 (2022: £30,877) were reimbursed or paid directly to two Trustees as follows;

Ms M E Graham (resigned 27/06/2023) received fees totalling £8,239 (2022: £30,195) in connection with her role as strategic advisor. The payments have been made in accordance with the charity's constitution and approved by the other trustees. A balance of £nil (2022: £2,634) is included within trade creditors as at the year end.

Ms T Shaish received a reimbursement of expenses in relation to a Charity Art project totalling £nil (2022: £682). The payments have been made in accordance with the charity's constitution and approved by the other trustees. No balance was outstanding at the year end.

9 Employees

The average monthly number of employees during the year was:

	2023	2022
	Number	Number
Administration	<u>6</u>	<u>6</u>

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

9 Employees	(Continued)	
Employment costs	2023	2022
	£	£
Wages and salaries	242,071	195,857
Social security costs	15,162	11,912
Other pension costs	5,248	2,643
	<u>262,481</u>	<u>210,412</u>

Last years employment costs were recharged to specific budget headings within the overall expenditure.

The number of employees whose annual remuneration was more than £60,000 is as follows:

	2023	2022
	Number	Number
£60,000 - £70,0000	<u>1</u>	<u>1</u>

10 Key management personnel

The key management personnel of the charity comprise the Trustees and the key management team as listed on page 1. The total amount of key management personnel benefits (including employer pension contributions and employer national insurance contributions) received by key management personnel for their services to the charity was £139,882 (2022: £179,533).

11 Taxation

The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.

12 Other gains and losses

	Unrestricted	Unrestricted
	funds	funds
	2023	2022
	£	£
Gains/(losses) upon:		
Foreign exchange	<u>15,469</u>	<u>(4,889)</u>

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

13 Debtors

	2023	2022
	£	£
Amounts falling due within one year:		
Trade debtors	56,726	58,392
Prepayments and accrued income	-	2,039
	<u>56,726</u>	<u>60,431</u>

14 Creditors: amounts falling due within one year

	Notes	2023	2022
		£	£
Other taxation and social security		5,047	8,478
Deferred income	15	113,674	145,149
Trade creditors		27,125	20,013
Other creditors		17,267	16,924
Accruals		21,646	5,520
		<u>184,759</u>	<u>196,084</u>

15 Deferred income

	2023	2022
	£	£
Other deferred income	<u>113,674</u>	<u>145,149</u>

Deferred income is included in the financial statements as follows:

	2023	2022
	£	£
Deferred income is included within:		
Current liabilities	<u>113,674</u>	<u>145,149</u>
Movements in the year:		
Deferred income at 1 January 2023	145,149	134,194
Released from previous periods	(145,149)	(134,194)
Resources deferred in the year	<u>113,674</u>	<u>145,149</u>
Deferred income at 31 December 2023	<u>113,674</u>	<u>145,149</u>

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

16 Restricted funds

The restricted funds of the charity comprise the unexpended balances of donations and grants held on trust subject to specific conditions by donors as to how they may be used.

	At 1 January 2023	Incoming resources	Resources expended	At 31 December 2023
	£	£	£	£
Website	-	98,241	(53,299)	44,942

The specific purpose for which the Restricted Funds are to be applied is for the development of the New Website.

17 Unrestricted funds

The unrestricted funds of the charity comprise the unexpended balances of donations and grants which are not subject to specific conditions by donors and grantors as to how they may be used. These include designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.

	At 1 January 2023	Incoming resources	Resources expended	Gains and losses	At 31 December 2023
	£	£	£	£	£
General funds	101,494	479,823	(517,385)	(15,469)	48,463
Previous year:					
	At 1 January 2022	Incoming resources	Resources expended	Gains and losses	At 31 December 2022
	£	£	£	£	£
General funds	347,244	324,364	(575,003)	4,889	101,494

18 Analysis of net assets between funds

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
Fund balances at 31 December 2023 are represented by:			
Current assets/(liabilities)	48,463	44,942	93,405
	48,463	44,942	93,405

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

18 Analysis of net assets between funds

(Continued)

	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £
Fund balances at 31 December 2022 are represented by:			
Current assets/(liabilities)	101,494	-	101,494
	<u>101,494</u>	<u>-</u>	<u>101,494</u>
	<u>101,494</u>	<u>-</u>	<u>101,494</u>

19 Related party transactions

There were no disclosable related party transactions during the year (2022 - none), other than those disclosed within the trustees note in note 8.

**PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)**

KEY REPORTS AND NOTES IN EURO EQUIVALENT AT THE YEAR END

These pages do not form part of the statutory financial statements

**PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
STATEMENT OF FINANCIAL ACTIVITIES
INCLUDING INCOME AND EXPENDITURE ACCOUNT (EURO)**

FOR THE YEAR ENDED 31 DECEMBER 2023

	Unrestricted funds	Unrestricted funds	Restricted funds	Restricted funds	Unrestricted funds	Unrestricted funds
	2023	2023	2023	2023	2022	2022
	£	€	£	€	£	€
Income from:						
Donations and legacies	24,134	27,849	-	-	22,472	25,341
Charitable activities	455,211	525,284	98,241	113,364	301,867	340,400
Investment income	<u>478</u>	<u>552</u>	<u>-</u>	<u>-</u>	<u>25</u>	<u>28</u>
Total income	<u>479,823</u>	<u>553,685</u>	<u>98,241</u>	<u>113,364</u>	<u>324,364</u>	<u>365,769</u>
Expenditure on:						
Charitable activities	<u>517,385</u>	<u>597,029</u>	<u>53,299</u>	<u>61,504</u>	<u>575,003</u>	<u>648,402</u>
Net income / (expenditure)	(37,562)	(43,344)	44,924	51,860	(250,639)	(282,633)
Other recognised gains and losses						
Other currency revaluation gains or losses	-	2,667	-	-	-	(21,893)
Other gains / (losses)	<u>(15,469)</u>	<u>(17,850)</u>	<u>-</u>	<u>-</u>	<u>4,889</u>	<u>5,513</u>
Net movement in funds	(53,031)	(58,527)	44,942	51,860	(245,750)	(299,013)
Fund balances at 1 January 2023	<u>101,494</u>	<u>114,450</u>	<u>-</u>	<u>-</u>	<u>347,244</u>	<u>413,463</u>
Fund balances at 31 December 2023	<u>48,463</u>	<u>55,923</u>	<u>44,942</u>	<u>51,860</u>	<u>101,494</u>	<u>114,450</u>

This page does not form part of the statutory financial statements

**PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
BALANCE SHEET (EURO)**

AS AT 31 DECEMBER 2023

	2023	2023	2022	2022
	£	€	£	€
Current assets				
Debtors	56,726	65,458	60,431	68,145
Cash at bank and in hand	<u>221,438</u>	<u>255,525</u>	<u>237,147</u>	<u>267,419</u>
	278,438	320,983	297,578	335,564
Creditors: amounts falling due within one year	<u>(184,759)</u>	<u>(213,200)</u>	<u>(196,084)</u>	<u>(221,114)</u>
Net current assets	<u>93,405</u>	<u>107,783</u>	<u>101,494</u>	<u>114,450</u>
Income funds				
Restricted funds	44,942	51,860	-	-
Unrestricted funds	<u>48,463</u>	<u>55,923</u>	<u>101,494</u>	<u>114,450</u>
Total funds	<u>93,405</u>	<u>107,783</u>	<u>101,494</u>	<u>114,450</u>

This page does not form part of the statutory financial statements

**PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (EURO)**

FOR THE YEAR ENDED 31 DECEMBER 2023

INCOME	Unrestricted funds	Unrestricted funds	Restricted funds	Restricted funds	Unrestricted funds	Unrestricted funds
	2023	2023	2023	2023	2022	2022
	£	€	£	€	£	€
Donations and legacies						
Donations and gifts	3,781	4,290	-	-	3,581	4,038
Membership fees	<u>20,416</u>	<u>23,559</u>	<u>-</u>	<u>-</u>	<u>18,891</u>	<u>21,303</u>
	<u>24,134</u>	<u>27,849</u>	<u>-</u>	<u>-</u>	<u>22,472</u>	<u>25,341</u>
Charitable activities						
Core income	298,307	344,227	98,241	113,364	246,968	278,493
Project income	154,146	177,874	-	-	134,173	151,300
Other income	<u>2,758</u>	<u>3,183</u>	<u>-</u>	<u>-</u>	<u>(79,274)</u>	<u>(89,393)</u>
	<u>455,211</u>	<u>525,284</u>	<u>98,241</u>	<u>113,364</u>	<u>301,867</u>	<u>340,400</u>
Investment income						
Interest receivable	<u>478</u>	<u>552</u>	<u>-</u>	<u>-</u>	<u>25</u>	<u>28</u>

This page does not form part of the statutory financial statements

**PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (EURO)**

FOR THE YEAR ENDED 31 DECEMBER 2023

EXPENDITURE	Unrestricted funds	Unrestricted funds	Restricted funds	Restricted funds	Unrestricted funds	Unrestricted funds
	2023	2023	2023	2023	2022	2022
	£	€	£	€	£	€
Charitable activities						
Direct costs						
Member organisation and board meetings	9,181	10,594	-	-	15,636	17,632
Advocacy communication and project development	76,604	88,396	42,339	48,856	89,700	101,150
Funded projects	43,313	49,980	-	-	59,445	67,033
Other direct costs	7,140	8,239	-	-	407	459
Freelancer costs	<u>102,672</u>	<u>118,477</u>	<u>8,586</u>	<u>9,908</u>	<u>180,742</u>	<u>203,814</u>
	<u>238,910</u>	<u>275,687</u>	<u>50,925</u>	<u>58,764</u>	<u>345,930</u>	<u>390,088</u>
Support costs						
Staff costs	260,138	300,182	2,343	2,704	210,412	237,271
Technology costs	3,288	3,794	31	36	2,944	3,320
Bad debts	192	222	-	-	241	272
Bank charges	314	362	-	-	256	289
Bookkeeping costs	3,960	4,570	-	-	3,886	4,382
Other support costs	2,685	3,098	-	-	3,831	4,320
Travel costs	560	646	-	-	3,857	4,349
Insurance	1,114	1,285	-	-	1,076	1,213
Governance costs	<u>6,224</u>	<u>7,182</u>	<u>-</u>	<u>-</u>	<u>2,570</u>	<u>2,898</u>
	<u>278,475</u>	<u>321,342</u>	<u>2,374</u>	<u>2,739</u>	<u>229,073</u>	<u>258,314</u>

This page does not form part of the statutory financial statements